TNF inhibitor
Janet Pope Janetbirdope
1 year 3 months ago
What is better in #PsA
#psoriatic #arthritis
#TNFi or #apremilast #PDE4i
#COREVITAS database study in #PsA
YOU can guess the answer!
1st line advanced RxTNFi lasts longer - retention
Vs PDE4i
#EULAR2024 @RheumNow @eular_org
POS0990 https://t.co/VmYG6Rj87c
Dr. Antoni Chan synovialjoints
1 year 3 months ago
Cycle or Swap? The swap strategy (SG) (i.e. from TNFi to IL17i) had higher retention rates compared to the change strategy (CG) choice in PsA patients who failed the first line of advanced treatment. The 5 years retention rate in SG was higher than in CG (57,8% vs 45,2%; p=0.1).… https://t.co/pH5rFI00vK https://t.co/XqTHO1tIr3
Janet Pope Janetbirdope
1 year 3 months ago
The age old question in #inflammatory #arthritis
Should you cycle within TNFi class or move on to another MOA in
#PsA #psoriatic #arthritis
Better retention to go to a IL17i vs another TNFi in observational study comparing the 2
POS0266
#EULAR2024 @RheumNow @eular_org https://t.co/CXcmYAG4m9
Janet Pope Janetbirdope
1 year 3 months ago
Can you predict which pts with
#PsA
#psoriatic #arthritis
Will respond to #TNFi #Rx?
Well, 🤔 maybe
Needs validation and an easy reliable inexpensive biomarker!
#EULAR2024 @RheumNow @eular_org
POS0992 https://t.co/Ce92561AMO
Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.
Aurelie Najm AurelieRheumo
1 year 3 months ago
Swedish/Danish cohort study in PsA
17000+ bionaïve 8000+ TNFi & 2000+ other MoA
Overall non melanoma skin cancer rate 651
(505 BCC & 87 SCC)
TNFi treated pts:
HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50)
HR 1.19 NMSC vs. other MoA (ns)
#EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6
Mrinalini Dey DrMiniDey
1 year 3 months ago
OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs
>1/2 D2T RA pts starting JAKi, RTX, IL-6Ri, or TNFi, but ~1/3 w abatacept, achieved remission or low disease activity in 6m & maintained consistent drug retention for 2yrs
@RheumNow #EULAR2024
Dr. Antoni Chan synovialjoints
1 year 3 months ago
In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150 @RheumNow https://t.co/vC4pgSKmfY
Mrinalini Dey DrMiniDey
1 year 3 months ago
OP0072 @RheumNow #EULAR2024
Effects of #Upadacitinib or #Adalimumab on pain in #RA
SELECT-COMPARE Phase 3 study
UPA & ADA led to improvements in pain vs PBO
PtGA & TJC28 pain improvement similar between UPA & ADA
➡️ UPA may be more effective in control of pain than ADA in RA
Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few presentations on this topic that will help us understand this progression from PsO to PsA better.
David Liew drdavidliew
1 year 3 months ago
More data from Jak-pot, the real-world multinational RA study, this time looking at infection in 14 national registries
JAKi (vs TNFi) had no signal for general/serious infection (excluding HZ)
Somewhat reassuring post-ORAL Surveillance infection data
#EULAR2024 OP0092 @RheumNow https://t.co/ocAbc4NiV2
Dr. Antoni Chan synovialjoints
1 year 3 months ago
Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024 @RheumNow https://t.co/vr5DvNOb21
Dr. Antoni Chan synovialjoints
1 year 3 months ago
A potentially notable association between TNFi in PsA and an increased risk of ischemic heart diseases and heart failure compared to IL-17i treatment. Limitations of the study noted. This may be due to patient selection and channeling of patients to the TNFi group and more… https://t.co/Q2LotHZwjQ https://t.co/uwl6vBIMsb
TheDaoIndex KDAO2011
1 year 3 months ago
Dr. G Schett reported using CAR-T cell Rx in patients w/ 1. pedi-SLE 2. CNS lupus 3. refractory cases with success. Post- Rx vaccine response is fine, infection risk is less since pts no longer need steroids. He is still following the pts for relapse and AEs @RheumNow #EULAR24
Poster Hall